Application of proteomic data in the translation of in vitro observations to associated clinical outcomes

Q1 Pharmacology, Toxicology and Pharmaceutics

Drug Discovery Today: Technologies Pub Date : 2021-12-01 DOI:10.1016/j.ddtec.2021.06.002

Sibylle Neuhoff , Matthew D. Harwood , Amin Rostami-Hodjegan , Brahim Achour

{"title":"Application of proteomic data in the translation of in vitro observations to associated clinical outcomes","authors":"Sibylle Neuhoff , Matthew D. Harwood , Amin Rostami-Hodjegan , Brahim Achour","doi":"10.1016/j.ddtec.2021.06.002","DOIUrl":null,"url":null,"abstract":"<div>Translation of information on drug exposure and effect is facilitated by in silico models that enable extrapolation of in vitro measurements to in vivo clinical outcomes. These models integrate drug-specific data with information describing physiological processes and pathological changes, including alterations to proteins involved in drug absorption, distribution and elimination. Over the past 15 years, quantitative proteomics has contributed a wealth of protein expression data, which are currently used for a variety of systems pharmacology applications, as a complement or a surrogate for activity of the corresponding proteins. In this review, we explore current and emerging applications of targeted and global (untargeted) proteomics in translational pharmacology as well as strategies for improved integration into model-based drug development.</div>","PeriodicalId":36012,"journal":{"name":"Drug Discovery Today: Technologies","volume":"39 ","pages":"Pages 13-22"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.ddtec.2021.06.002","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today: Technologies","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S174067492100010X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 3

Abstract

Translation of information on drug exposure and effect is facilitated by in silico models that enable extrapolation of in vitro measurements to in vivo clinical outcomes. These models integrate drug-specific data with information describing physiological processes and pathological changes, including alterations to proteins involved in drug absorption, distribution and elimination. Over the past 15 years, quantitative proteomics has contributed a wealth of protein expression data, which are currently used for a variety of systems pharmacology applications, as a complement or a surrogate for activity of the corresponding proteins. In this review, we explore current and emerging applications of targeted and global (untargeted) proteomics in translational pharmacology as well as strategies for improved integration into model-based drug development.

Abstract Image

查看原文本刊更多论文

蛋白质组学数据在将体外观察转化为相关临床结果中的应用

通过计算机模型，可以将体外测量结果外推到体内临床结果，从而促进了药物暴露和效果信息的翻译。这些模型将药物特异性数据与描述生理过程和病理变化的信息整合在一起，包括参与药物吸收、分布和消除的蛋白质的改变。在过去的15年中，定量蛋白质组学提供了丰富的蛋白质表达数据，这些数据目前用于各种系统药理学应用，作为相应蛋白质活性的补充或替代。在这篇综述中，我们探讨了靶向和全局(非靶向)蛋白质组学在翻译药理学中的当前和新兴应用，以及改进整合到基于模型的药物开发中的策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Discovery Today: Technologies Pharmacology, Toxicology and Pharmaceutics-Drug Discovery

自引率

0.00%

发文量

期刊介绍： Discovery Today: Technologies compares different technological tools and techniques used from the discovery of new drug targets through to the launch of new medicines.